Pay in 4 interest-free payments of $5.78 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
What is happening now is that we are treating many patients who would benefit most from metabolic surgery with OMM, while still failing to treat the vast majority of people living with obesity who would benefit from any evidence-based treatment
nearest neighbor type: NN-descent
doi:10.1136/bmj.316.7140.1295
February 14, 2023
470 One could argue that the success of sodium-glucose cotransporter 2 (SGLT2) inhibitors, and now of GLP-1RAs, suggests that metabolic abnormalities play an important role in driving HFpEF
Funding Financial support: Dr
US$ 29.26
US$ 29.26
US$ 28.02
US$ 23.68
US$ 24.31
US$ 23.05
US$ 28.34
US$ 26.70
US$ 21.69
US$ 21.54
